Video Experimental Relacionado
Updated: Aug 11, 2025
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.3K
Desmitificando la drogabilidad de la familia de oncogenes MYC
Nishant M Karadkhelkar1, Mingliang Lin1, Lisa M Eubanks1
1Department of Chemistry, Department of Immunology and Microbial Science, The Skaggs Institute for Chemical Biology, and WIRM Institute for Research and Medicine, The Scripps Research Institute, La Jolla, California 92037, United States.
Journal of the American Chemical Society
|February 3, 2023
Resumen
Los oncogenes MYC impulsan el cáncer mediante la regulación de la progresión del ciclo celular. A pesar de los desafíos, dirigirse al complejo MYC-MAX es una estrategia terapéutica viable para numerosos cánceres humanos.
Área de la Ciencia:
- En el campo de la oncología
- Biología molecular
- La bioquímica
Sus antecedentes:
- La familia de oncogenes MYC (MYC, MYCN y MYCL) son reguladores críticos de la progresión del ciclo celular.
- La desregulación de los genes de la familia MYC es una característica de más de la mitad de todos los cánceres humanos, lo que contribuye al inicio y mantenimiento.
- El papel de MYC se extiende a los cánceres que normalmente no están asociados con su etiología directa, destacando su amplio impacto oncogénico.
Objetivo del estudio:
- Revisar la bioquímica de MYC y su interacción con MAX en el contexto de la progresión del cáncer.
- Desafiar la noción de que el MYC no es farmacológico y explorar estrategias terapéuticas alcanzables.
- Discutir el potencial de la orientación de MYC-MAX para el tratamiento del cáncer.
Principales métodos:
- Análisis bioquímico de la heterodimerización de MYC-MAX.
- Revisión de la literatura existente sobre el papel de MYC en la oncogénesis.
- Discusión de las estrategias terapéuticas dirigidas a MYC-MAX.
Principales resultados:
- La formación del complejo MYC-MAX es esencial para la regulación transcripcional de numerosos genes involucrados en el cáncer.
- La sobreexpresión o amplificación, en lugar de la mutación, impulsa la función oncogénica de MYC.
- A pesar de una gran superficie de interacción, el objetivo de MYC-MAX es factible, con potencial para una ventana terapéutica.
Conclusiones:
- El MYC es un factor oncogénico crucial con un papel importante en diversos tipos de cáncer en humanos.
- La dificultad percibida en la orientación de la interacción MYC-MAX está siendo superada por los enfoques terapéuticos emergentes.
- La modulación de MYC ofrece una vía prometedora para el tratamiento del cáncer, desafiando su estatus de "indrugable".
Videos de Conceptos Relacionados
01:06Induced Pluripotent Stem Cells
4.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.2K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:25Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
02:38Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K